Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 22-23: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Gxplex admin (talk | contribs) m 1 revision imported Β |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 | ||
| | |module=4 | ||
| | |unit=4.4.0 | ||
| | |scope=HM | ||
| | |doc_part=Article 22-23 | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
|contributors= | |||
Β | |tags=TAG-00041-Ame-run ++ TAG-00017-Spo-die ++ TAG-00057-Com-deR ++ TAG-00008-Cli-ngK | ||
|tags_display=[[Glossary:TAG-00041-Ame-run|Amendment]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00057-Com-deR|Competent authority]], [[Glossary:TAG-00008-Cli-ngK|Clinical trial]] | |||
Β | |comment=Amendments to clinical trial authorisation: general rules | ||
|content=Amendments to clinical trial authorisation | |||
|- | |||
|- | |||
|- | |||
| Β | |||
| | |||
| | |||
Β | |||
= | |||
Amendments to clinical trial authorisation | |||
22.Β Subject to regulation 30, an amendment to a clinical trial authorisation may be madeβ | 22.Β Subject to regulation 30, an amendment to a clinical trial authorisation may be madeβ | ||
Β Β (a)by the licensing authority, in accordance with regulation 23; or | Β Β (a)by the licensing authority, in accordance with regulation 23; or | ||
| Line 59: | Line 26: | ||
Β Β (a)shall take those representations into account before deciding whether to make the amendment; and | Β Β (a)shall take those representations into account before deciding whether to make the amendment; and | ||
Β Β (b)may delay the date the proposed amendment is to take effect, in order to allow time for them to consider those representations. | Β Β (b)may delay the date the proposed amendment is to take effect, in order to allow time for them to consider those representations. | ||
}} | |||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 β Unit 4.4.0 |
| Scope | HM |
| Document part | Article 22-23 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Amendment, Sponsor, Competent authority, Clinical trial |
Content
Amendments to clinical trial authorisation 22. Subject to regulation 30, an amendment to a clinical trial authorisation may be madeβ
(a)by the licensing authority, in accordance with regulation 23; or (b)by the sponsor, in accordance with regulation 24 or 25.
Amendments by the licensing authority 23.β(1) Subject to paragraphs (1) and (2), the licensing authority may make amendments to a clinical trial authorisation if it appears to the authority to be necessary to ensureβ
(a)the safety or scientific validity of the clinical trial; or (b)that the conditions and principles of good clinical practice are satisfied or adhered to in relation to the clinical trial.
(2) Where the licensing authority propose to make an amendment in accordance with paragraph (1), the authority shall, at least 14 days before the date on which it is proposed the amendment should take effect, serve a notice on the sponsor stating their proposal and the reasons for it.
(3) If, within 14 days of the date a notice is served in accordance with paragraph (2), the sponsor makes representations in writing to the licensing authority, the authorityβ
(a)shall take those representations into account before deciding whether to make the amendment; and (b)may delay the date the proposed amendment is to take effect, in order to allow time for them to consider those representations.
